Rigel Pharmaceuticals, Inc. (RIGL) investor relations documents from the company's IR site: 3 presentations, 1 press release; latest deck 2026-08-13. Read in-app with summaries. First-party data.
Presentation: Rigel's corporate presentation details its transformational growth strategy, including the in-licensing of VEPPANU and projected revenue growth to $260M in 2026.
| Published | Type | Document |
|---|---|---|
| 2026-08-13 | Presentation | Presentation |
| 2026-05-12 | Presentation | View Presentation |
| 2026-05-05 | Earnings deck | Earnings Presentation |
| 2026-05-05 | Press release |
RIGL overview · RIGL earnings · RIGL financials · RIGL KPIs · RIGL documents · RIGL ownership · RIGL peers
Documents published by the company on its investor-relations site; summaries are model-written. Not personalized investment advice.